Acesso livre
Acesso livre

Arquivos do dia: Outubro 28, 2021

Estudo randomizado | Tratamento precoce com fluvoxamina reduziu o risco de cuidado de emergência e internação entre pacientes com COVID-19.

28 Out, 2021 | 16:22h

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial – The Lancet Global Health

Comentários:

Expert reaction to study looking at fluvoxamine as a COVID-19 treatment in high-risk outpatients with early-diagnosed COVID-19 – Science Media Centre

The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM

The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews

Conteúdos relacionados:

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Comentário no Twitter

 

Estudo randomizado | Tratamento precoce da Covid-19 com sotrovimabe (anticorpo neutralizante do SARS-CoV-2) está associado a risco reduzido de internação.

28 Out, 2021 | 16:18h

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab – New England Journal of Medicine

 

Comentário no Twitter

 

Merck autoriza que outros países produzam novo antiviral contra COVID-19.

28 Out, 2021 | 16:17h

Merck to allow other nations to produce new COVID-19 antiviral – CIDRAP

Ver também:

Merck will allow drugmakers in other countries to make its COVID-19 pill – NPR

Game-Changing COVID-19 Oral Treatment Set To Become Widely Accessible in Low- and Middle-Income Countries Upon Regulatory Approval – Health Policy Watch

Conteúdos relacionados:

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Dois estudos observacionais levantam dúvidas sobre os efeitos do fechamento de escolas na redução da transmissão da Covid-19.

28 Out, 2021 | 16:15h

Estudo 1: No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020 – Nature Medicine

Estudo 2: The impact of school opening model on SARS-CoV-2 community incidence and mortality – Nature Medicine

 

Comentários no Twitter

(fio – clique para saber mais)

 

O que as vacinas contra COVID em crianças mais novas podem significar para a pandemia.

28 Out, 2021 | 16:14h

What COVID vaccines for young kids could mean for the pandemic – Nature

Conteúdo relacionado: FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

Confusão mental (brain fog) pode persistir durante meses após o diagnóstico de COVID.

28 Out, 2021 | 16:11h

Assessment of Cognitive Function in Patients After COVID-19 Infection – JAMA Network Open

Comentários:

Brain fog can persist 8 months after COVID diagnosis – CIDRAP

Brain fog in Covid-19 patients can persist for months, even in those who were not hospitalized, study finds – CNN

Subfenótipos longitudinais respiratórios em pacientes com síndrome da angústia respiratória aguda associada a COVID-19: resultados de 3 estudos de coorte observacionais.

28 Out, 2021 | 16:10h

Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts – The Lancet Respiratory Medicine

Comentários:

COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions – The Lancet Respiratory Medicine

Respiratory Subphenotypes of COVID-19-Related ARDS – ICU Management & Practice

 

Comentário no Twitter

 

Documento de Consenso da ESC | Fragilidade do idoso na cardiologia: definição, avaliação e implicações clínicas para a cardiologia geral.

28 Out, 2021 | 16:08h

Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS) – European Journal of Preventive Cardiology

Revisão sistemática | Antibióticos profiláticos para prevenir infecções por Gram-positivos associadas a cateter venoso central de longa permanência em adultos e crianças em tratamento oncológico.

28 Out, 2021 | 16:07h

Prophylactic antibiotics for preventing gram‐positive infections associated with long‐term central venous catheters in adults and children receiving treatment for cancer – Cochrane Library

Revisão sistemática | Não uso de mamadeiras durante o estabelecimento da amamentação em recém-nascidos prematuros – “Evitar o uso de mamadeiras quando os prematuros necessitam de suplementos alimentares provavelmente aumenta a duração de qualquer amamentação após a alta.”

28 Out, 2021 | 16:04h

Avoidance of bottles during the establishment of breastfeeds in preterm infants – Cochrane Library

Resumo: Avoidance of bottles during the establishment of breastfeeds in preterm infants – Cochrane Library

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.